Mechanism of Action of Terlipressin
Terlipressin is a synthetic vasopressin analog that functions both as a prodrug for lysine-vasopressin and as a direct vasoconstrictor, with twice the selectivity for vasopressin V1 receptors over V2 receptors, leading to splanchnic vasoconstriction that increases effective arterial blood volume, mean arterial pressure, and renal blood flow. 1
Pharmacological Mechanism
Terlipressin works through a dual mechanism:
- Direct V1 receptor stimulation: Acts immediately on vascular smooth muscle vasopressin V1 receptors, causing vasoconstriction 1
- Prodrug conversion: Tissue peptidases cleave N-terminal glycyl residues to release the active metabolite lysine-vasopressin, providing sustained vasoconstrictive effects 1
The V1 receptor selectivity (2:1 ratio over V2 receptors) is clinically important because it maximizes vasoconstriction while minimizing antidiuretic effects 1.
Hemodynamic Effects
Within 5 minutes of administration, terlipressin produces measurable hemodynamic changes that persist for at least 6 hours 1:
- Mean arterial pressure: Increases by approximately 16.2 mmHg (maximum effect at 1.2-2 hours)
- Heart rate: Decreases by approximately 10.6 beats/minute
- Portal pressure: Reduces hepatic venous pressure gradient from 22.2 to 19.1 mmHg in patients with variceal hemorrhage 2
Clinical Applications Based on Mechanism
Hepatorenal Syndrome-AKI (Primary FDA-Approved Indication)
The pathophysiology of HRS-AKI involves extreme splanchnic vasodilation causing low effective arterial blood volume, with compensatory renal vasoconstriction 2. Terlipressin counteracts this by reducing portal hypertension and splanchnic blood flow, which increases effective arterial volume and restores renal perfusion 2, 1.
- Improves renal blood flow and glomerular filtration rate
- Reverses HRS-AKI in 29-60% of cases when combined with albumin 2, 3
- Reduces need for renal replacement therapy 2
The albumin co-administration enhances terlipressin's effect by filling the central circulation, optimizing the benefit of splanchnic vasoconstriction on renal blood flow 2.
Variceal Hemorrhage (Not FDA-Approved in US)
Through splanchnic vasoconstriction, terlipressin reduces portal venous pressure and flow, decreasing pressure in esophageal varices 2. However, octreotide is preferred in the US due to terlipressin's 2.39-fold higher adverse event rate 2.
Pharmacokinetic Profile
- Half-life: 0.9 hours for terlipressin; 3.0 hours for lysine-vasopressin 1
- Clearance: 27.4 L/hr (terlipressin); 318 L/hr (lysine-vasopressin) 1
- Metabolism: Not metabolized in blood/plasma; tissue peptidases throughout the body perform the conversion 1
- Excretion: <1% excreted unchanged 1
Important Caveats
Terlipressin does not impact the underlying liver disease, which explains why mortality benefits are limited despite improvements in renal function 2. The drug treats the hemodynamic consequences of cirrhosis but not the hepatic pathology itself.
The ubiquitous distribution of peptidases means metabolism is unlikely to be affected by disease state or drug interactions, providing predictable pharmacokinetics even in critically ill patients 1.